ARO-C3

Arrowhead Pharmaceuticals' ARO-C3 demonstrated significant efficacy in IgA nephropathy patients, achieving mean C3 reductions of 89% and sustained reductions exceeding 87% through week 24 of the Phase 1/2 trial.

Arrowhead Pharmaceuticals announced FDA acceptance of its New Drug Application for plozasiran to treat familial chylomicronemia syndrome (FCS), with a PDUFA date of November 18, 2025.

Arrowhead Pharmaceuticals has submitted an NDA to the FDA for plozasiran, targeting familial chylomicronemia syndrome (FCS), a rare genetic disease with no approved treatments.